Why is "Moclobemide" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-08 13:21:16
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Moclobemide entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-08 and was most recently seen on 2026-08-08.
Wikipedia Overview
Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the United Kingdom and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
A new review compares antidepressant side effects - STAT
-
Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression - Nature
-
MAO inhibitors for treatment-resistant... : Pharmacological Research - ovid.com
-
Antidepressant drugs in the treatment of anxiety disorders - Cambridge University Press & Assessment
-
Efficacy of Pharmacotherapies for Bulimia Nervosa: A Systematic Review and Meta-Analysis - psychiatryonline.org
-
Dextroamphetamine-Amphetamine Augmentation in the Treatment of Treatment-Resistant Depression - Cureus
-
Successfully Prescribing MAOIs for Depression - Psychiatric Times
-
Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation - Frontiers
-
Triptan interactions - The Pharmaceutical Journal
-
Management of Antidepressant-Induced Sexual Dysfunction: A Literature Review - Cureus
-
Accelerated enzyme engineering by machine-learning guided cell-free expression - Nature
-
New drugs, old problems: Revisiting… Pharmacological management of treatment-resistant depression - Cambridge University Press & Assessment
-
Antidepressant-Induced Liver Injury: A Review for Clinicians - psychiatryonline.org
-
MAO Inhibitors: Is Concomitant Use Safe or Too Risky? - Psychiatric Times
-
What Is the Best Medication for Seasonal Affective Disorder Symptoms? - Psych Central
-
Serotonin and Drug-Induced Therapeutic Responses in Major Depression, Obsessive–Compulsive and Panic Disorders - Nature
-
Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study - psychiatryonline.org
-
The Corticosteroid Receptor Hypothesis of Depression - Nature
-
Why quitting smoking is so miserable - The Globe and Mail
-
PTSD – an update for general practitioners - Royal Australian College of General Practitioners (RACGP)
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.